XML 27 R13.htm IDEA: XBRL DOCUMENT v3.26.1

Cash, Cash Equivalents, and Financial Instruments

12 Months Ended

Dec. 31, 2025

Cash and Cash Equivalents [Abstract]

Cash, Cash Equivalents, and Financial Instruments

Note 3 – Cash, Cash Equivalents, and Financial Instruments

The following table shows the Company’s cash, cash equivalents, and marketable investment securities by significant investment category:

 Schedule of Cash, Cash Equivalents and Marketable Investment Securities

		December 31, 2025
		Adjusted Cost				Total Unrealized Gains / (Losses)				Fair Value				Cash and Cash Equivalents				Marketable Investment Securities
Cash		$	11,884,607			$	-			$	11,884,607			$	11,884,607			$	-
Total		$	11,884,607			$	-			$	11,884,607			$	11,884,607			$	-

		December 31, 2024
		Adjusted Cost				Total Unrealized Gains / (Losses)				Fair Value				Cash and Cash Equivalents				Marketable Investment Securities
Cash		$	2,936,544			$	-			$	2,936,544			$	2,936,544			$	-
Level 2:
U.S. treasury securities			26,392,655				418,443				26,811,098				-				26,811,098
Subtotal			26,392,655				418,443				26,811,098				-				26,811,098
Total		$	29,329,199			$	418,443			$	29,747,642			$	2,936,544			$	26,811,098

X

- References

No definition available.

+ Details

Name:	us-gaap_CashAndCashEquivalentsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure of cash, cash equivalent, and debt and equity securities, including realized and unrealized gain (loss).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/320/tableOfContent

+ Details

Name:	us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration